CSG's €17bn Backlog and New Defence Ventures Overshadowed by Persistent Selling Pressure

CSG shares have dropped 58% from Jan highs despite record orders, Q1 revenue growth, and expansions into Alzchem chemicals and Ukraine ammo production, with RSI at 31.8.

The Czechoslovak Group is delivering record orders and expanding across multiple fronts, yet its stock continues to slide. Shares closed Friday at €15.05, shedding 3.62% on the day and 16.68% over the past seven trading sessions. The gap between operational momentum and market sentiment has rarely been wider.

From the January high of €36.05, the stock has now surrendered 58.26% of its value. At current levels, it sits just 10.29% above the May trough of €13.65, reached on 4 May 2026. The RSI, at 31.8, signals intense selling pressure, while annualised 30-day volatility stands at 76.98%, explaining the sharp swings on even modest news flow.

A Chemie-Stake and a Strategic Reach

The most prominent move last week was CSG's expansion into German speciality chemicals. On 2 June, Alzchem disclosed that CSG, via its subsidiary STALUNA TRADE, now holds 9.9% of its voting rights. Combined with cash-settled total return swaps covering roughly 10.2% of voting rights, the total position reaches 20.1%. The swaps run until May 2027 and do not confer direct voting rights. Alzchem said CSG has described itself as a long-term-oriented investor, while its own management and strategy remain unchanged.

Alzchem produces nitroguanidine, a key raw material for propellants and munitions. It reported 2025 revenue of €562.1 million and EBITDA of €116.5 million. For CSG, the move extends its capital allocation clearly into speciality chemicals, broadening a profile traditionally centred on defence, munitions and land systems.

Ukraine, Slovakia and the KNDS Puzzle

The market's indifference to the Alzchem stake is matched by its muted response to other developments. On 1 June, a new production line came online in Ukraine under a licensing partnership with Ukrainian Armor. It will manufacture NATO-standard 155mm artillery shells at an annual capacity of 100,000 units and 105mm shells at 50,000 units. Technology and high-grade components come from the Czech Republic, with final assembly on Ukrainian soil.

In Slovakia, CSG is pushing ahead with two projects simultaneously. A new line for long-range ammunition with an annual capacity of 70,000 units is already running at full load. Separately, a joint venture with South Africa's Reunert will produce electronic fuzes under the name Fuchs Electronics Europe, split 51-49 in Reunert's favour. CSG is contributing infrastructure from its ZVS Dubnica nad Váhom site.

The most ambitious initiative remains unconfirmed. According to Reuters, CSG has expressed interest in a stake in the Franco-German defence group KNDS, one of Europe's leading manufacturers of tanks and artillery systems. The German family shareholders are said to favour an IPO and participation by the German federal government instead. Neither the size nor the valuation of any potential transaction has been disclosed.

Record Numbers Meet Cautious Analysts

The first quarter of 2026 underscored the operational case. Revenue rose 13.8% year-on-year to €1.544 billion, while operating EBIT reached €372 million, yielding a margin of 24.1%. Net profit surged 83% to €299 million, lifting the net margin from 12% to 19%. The order book hit a record €17 billion, up from €15 billion at end-2025, and the negotiation pipeline stands at €27 billion.

CSG reaffirmed its full-year guidance: revenue of €7.4–7.6 billion, an operating EBIT margin of 24–25%, an investment rate of roughly 8.5% of revenue, and net debt-to-EBITDA below 1.3 by year-end.

Ten analysts rate the stock a 'Strong Buy' with a median target of €32.05 — more than double the current price. Berenberg, however, recently trimmed its estimates and lowered its price target, citing uneven segment performance in the first quarter.

Technical Damage and the Next Threshold

Chartwise, the stock remains severely wounded. It is trading 23.44% below its 50-day moving average of €19.66, a level that now acts as firm resistance. The zone above the May low of €13.65 is the immediate support. If it holds, a short-term stabilisation is possible. A break would mark a new trough in the current bear phase.

Investors appear to be demanding more than announcements — they want evidence of sustainable cash flow and disciplined execution. Whether the Alzchem stake evolves into an industrial partnership or stays a financial bet, and whether the KNDS interest becomes concrete, will likely be clarified with the half-year numbers due in August 2026. Until then, the gulf between operational strength and market valuation defines the narrative.